HALISTER1: Sanofi Diabetes Decline Offset by Multiple Sclerosis Growth: JPM

Sanofi Diabetes Decline Offset by Multiple Sclerosis Growth: JPM

(Bloomberg) -- JPMorgan’s Sanofi profitability analysis suggests falling profits from its diabetes treatment business is largely reflected in consensus and is offset by growth in the multiple sclerosis franchise, analysts including Richard Vosser write in client note.
  • Upgrades stock to neutral and raises PT to EU87 from EU71
  • No longer sees downside to consensus EPS, though risks to product launches, including Dupixent and Praluent remain
  • MS franchise is driven by high incremental profitability from Aubagio sales until 2021 when assumes Aubagio faces genericisation, though sees risk before this date

Alert: HALISTER1
Source: BFW (Bloomberg First Word)

Tickers
SAN FP (Sanofi)

To de-activate this alert, click here
To modify this alert, click here

UUID: 7947283

HALISTER1: INDIA RATINGS: Everest Building Cut; Singer India Raised

INDIA RATINGS: Everest Building Cut; Singer India Raised

(Bloomberg) -- Here’s a roundup of Indian co. debt-rating changes.
  • To get this story sent to your inbox real-time, run NI INRATINGS , click on Display & Edit, then Set Alert Delivery
DOWNGRADE
  • Everest Building
    • Fund-based limits, non fund-based limits cut to A(SO) from A+(SO) at ICRA
    • Cites revision in ratings of parent Everest Industries
UPGRADE
  • Singer India
    • Cash credit raised to BBB from BBB- at ICRA
    • Cites sustained improvement in scale of operations

Alert: HALISTER1
Source: BFW (Bloomberg First Word)

Tickers
SING IN (Singer India Ltd)

To de-activate this alert, click here
To modify this alert, click here

UUID: 7947283